Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Sunesis Pharmaceuticals Inc (NASDAQ:SNSS)

2.03
Delayed Data
As of Sep 21
 -0.0101 / -0.50%
Today’s Change
1.86
Today|||52-Week Range
5.00
-43.93%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$48.0M

Company Description

Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Its efforts are currently focused primarily on the development of vosaroxin for the treatment of acute myeloid leukemia. The firms activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA.

Contact Information

Sunesis Pharmaceuticals, Inc.
395 Oyster Point Boulevard
South San Francisco California 94080
P:(650) 266-3500
Investor Relations:

Employees

Shareholders

Other institutional45.26%
Mutual fund holders4.68%
Individual stakeholders0.66%

Top Executives

Daniel N. SwisherPresident, CEO, CFO, Secretary & Director
Judith A. FoxChief Scientific Officer
Gene C. JamiesonVice President-Technical Operations
Jennifer A. SmithVice President-Biometrics
Parvinder S. HyareVice President-Global Oncology Operations